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INTRODUCTION
Alzheimer disease (AD) is the main cause
of dementia and loss of functional inde-
pendence in the elderly (Aisen, 2010; Vellas
and Aisen, 2010). AD is a chronic neu-
rodegenerative disease characterized by a
progressive decline of cognitive perfor-
mance with a deleterious impact on social
activities. AD is a worldwide big concern
because of its adverse consequences and
its expanding prevalence and incidence
(Aisen, 2010; Vellas and Aisen, 2010). In
order to reduce AD impact at an indi-
vidual level and in terms of health and
social costs, the development of efficient
therapeutic strategies proves necessary.
Regrettably, the development of all cur-
rent specific medications is unsuccessful in
clinical development phases (Birks, 2006;
McShane et al., 2006; Anand et al., 2014).
However, an interesting fact is that the
prevalence of dementia in the general pop-
ulation might still be subject to changes.
Indeed, a reduction in the prevalence
of dementia is reported among English
community-dwellers over the past two
decades (Matthews et al., 2013). So, even
if some factors, such as the increased life
expectancy beyond 80 years, are unavoid-
able and augment the global prevalence
of dementia, others may instead reduce
its prevalence. For instance, efficient pri-
mary prevention of cardio-vascular disease
is suspected to explain the reduced preva-
lence of dementia in England (Matthews
et al., 2013). In the same vein, vitamin D,
an “old” molecule primarily known for its
effects on the bone, has been singled out
in the last decade as an important bio-
logical component able to influence the
natural history of AD. Here, we wish to
highlight the difficulties experienced by
the research on curative treatments and, in
contrast, the prospects offered by multi-
target drugs, especially those based on
vitamin D.
TREATMENTS RESEARCH IN
ALZHEIMER DISEASE: THE IRONY OF
CURATIVE THERAPIES
The only drugs currently available (i.e.,
cholinesterase inhibitors and memantine)
slow down without changing the natu-
ral history of AD (Birks, 2006; McShane
et al., 2006). Because of their symp-
tomatic action, they are intended only for
patients with mild-to-severe AD. Thus,
one of the main AD challenges over the
coming decade lies in the finding of a
curative drug (Vellas and Aisen, 2010).
Recent research has focused on “disease-
modifying” medications to intervene in
the pathogenesis of the disease, able to
halt or slow the neurodegenerative pro-
cess. To date, strategies to develop disease-
modifying drugs have mainly targeted
amyloid-β peptide (accumulation, aggre-
gation, clearance) and/or the “tubulin
associated unit” (TAU protein: phospho-
rylation and aggregation) by active and
passive immunotherapy (Vellas and Aisen,
2010; Anand et al., 2014). Unfortunately
candidate drugs, such as bapineuzumab,
have failed in phase III clinical trials con-
ducted in mild-to-moderate AD (Anand
et al., 2014).
Because the earlier the disease-
modifying treatment starts, the greater
is the possibility of efficacy, it is impor-
tant to initiate the treatment before the
clinical manifestation of the overt dis-
ease. This is one of the reasons of the
interest for the early diagnosis of AD.
Importantly, this research has identified
new morphological as well as functional
and biological criteria that, combined with
the classical neuropsychological expertise,
help make the diagnosis of AD earlier
and earlier (Schrötter et al., 2013). Such
accuracy of the diagnosis of early-stage
AD led in memory clinics to a drastic
selection of participants for the curative
clinical trials, with consequent substan-
tial recruitment difficulties. The second
consequence of this hyperselection was
to address only a fraction of the patients
followed in memory clinics, predomi-
nantly those with the prodromal stage
of AD. For instance, the French National
Centre for the Management of Trials on
Healthcare Products (CeNGEPS), which
involves more than ten university mem-
ory clinics (UMCs) in France, included
in 2009 only 260 participants in clini-
cal trials, although there were potentially
24,000 patients available in these cen-
ters. In other words, the curative drugs
are addressing only 1.1% of AD patients
followed in French UMCs. The question
is then what can be offered to all other
patients.
TREATMENTS RESEARCH IN
ALZHEIMER DISEASE: THE
MULTI-TARGET DRUGS
In addition to curative treatments, two
other therapeutic approaches should be
considered in AD. The first one is the non-
drug-based approach, which is a multi-
domain intervention designed to stimulate
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AD patients (de Sant’Anna and Morat,
2013). The second one is the multi-
target drug approach, meaning that the
treatment administered to AD patients
simultaneously targets several neurode-
generative processes (Cavalli et al., 2008).
The latter approach offers the opportu-
nity to combine current standard anti-
dementia symptomatic drugs with other
neuroprotective agents to build a multi-
regimen with multi-target effects. This
questioning is central since patients at
later stages of AD (i.e., with symptoms)
could benefit from this new therapeutics,
thus reducing chance inequalities between
AD patients. In addition, it could bene-
fit a larger number of patients and could
be easily implemented compared with
current trials, since it targets diagnosed
patients who are already using a symp-
tomatic treatment. Among the candidate
molecules is the vitamin D, which has
demonstrated in the last decade numerous
neurological effects.
VITAMIN D AND ALZHEIMER DISEASE:
FROM AN INTRIGUING IDEA TO A
THERAPEUTIC OPTION
About one billion people are deficient in
vitamin D throughout the world. Older
adults are especially affected, in partic-
ular those with AD with a prevalence
of approximately 70–90% (Holick, 2007;
Annweiler et al., 2011).
Besides its classical function of bone
metabolism regulation, vitamin D has
exhibited multiple biological targets medi-
ated by its nuclear hormone receptor,
the Vitamin D Receptor (VDR) (Kalueff
and Tuohimaa, 2007; Annweiler et al.,
2010). Specific actions on target organs
such as the central nervous system (CNS)
have been described, providing evidence
for a neurosteroid action of vitamin D
(Kalueff and Tuohimaa, 2007). In partic-
ular, VDRs are present in neurons and
glial cells of the hippocampus, cortex and
sub-cortex, all regions essential to cog-
nition. The binding of vitamin D on
the VDRs triggers neuronal protection
against AD degenerative processes, includ-
ing anti-inflammatory action, antioxidant
effect, control of calcium homeostasis by
regulating the concentration of intracel-
lular calcium in hippocampal neurons,
anti-atrophic effect by regulating neu-
rotrophic agents, attenuation of Aß42
peptide accumulation by stimulating the
phagocytosis of Aß peptide together with
enhancing brain-to-blood Aß efflux trans-
port at the blood-brain barrier, and
the prevention of acetylcholine defect by
increasing the activity of choline acetyl-
transferase (thus the bioavailability of
acetylcholine) in the brain (Kalueff and
Tuohimaa, 2007; Annweiler et al., 2010;
Annweiler and Beauchet, 2011). These
experimentally-described neuroprotective
properties of vitamin D may help, in the
case of normalized vitamin D status, to
address against the decline of brain func-
tion in AD, especially against cognitive
decline (Figure 1).
Epidemiology is consistent with this
notion, and has repeatedly shown that
low serum concentrations of vitamin D
are cross-sectionally associated with global
cognitive impairment (Annweiler et al.,
2009), the people with hypovitaminosis
D having more cognitive disorders (Etgen
et al., 2012), specifically more executive
dysfunctions (Annweiler et al., 2013a).
Specifically, it has been reported that
people with AD have lower vitamin D
status than controls (Annweiler et al.,
2013b). They also exhibit increased lev-
els of vitamin D-binding protein (Moon
et al., 2013) and lower levels of 25-
hydroxyvitamin D in the cerebrospinal
fluid (Johansson et al., 2013) compared
to controls. Longitudinal prospective stud-
ies have enabled to better understand
this association and have reported a tem-
poral sequence, with hypovitaminosis D
preceding the onset of cognitive decline
(Llewellyn et al., 2010).
Recent biomedical literature further
suggests that the VDRs may confer genetic
risk for AD. Some human variants appear
less sensitive to vitamin D and more
likely to experience cognitive decline. For
instance, AD patients have reduced lev-
els of VDR mRNA (Sutherland et al.,
1992). In contrast, it has been reported
that the overexpression of VDR may sup-
press amyloid precursor protein transcrip-
tion (Wang et al., 2012). A significant asso-
ciation has also been shown between the
VDR gene APA1 polymorphism and the
onset of AD, the Aa genotype multiplying
by 2.3 the risk of AD compared to the AA
genotype (Gezen-Ak et al., 2007).
It seems thus crucial to maintain high
vitamin D levels in the elderly, especially
in those with AD. In line with this, high
intake of vitamin D (whether from food,
supplements, or sun exposure) is associ-
ated with better cognitive function in older
individuals. Having more than 800UI of
vitamin D supplies per day divides the
risk of AD by 5 after 7 years of follow-
up (Annweiler et al., 2012a). This neu-
roprotective effect has been confirmed by
clinical comparative trials reporting cogni-
tive improvement after vitamin D supple-
mentation whether in general aged pop-
ulation (Prybelski et al., 2008; Annweiler
et al., 2012b) or in patients who already
have symptoms of AD (Stein et al., 2011).
The cognitive benefits of supplementation
appear at 4 weeks (Prybelski et al., 2008),
and particularly for executive functions
and processing speed (Annweiler et al.,
2013a).
It has to be noted yet that, although
most of older adults have hypovita-
minosis D, not all develop AD. It is thus
unlikely that hypovitaminosis D alone
explains the onset of AD, and that vita-
min D supplementation is sufficient to
prevent AD by itself. One solution might
thus be to combine vitamin D with
a symptomatic anti-dementia treatment
to build a multi-target drug (Annweiler
and Beauchet, 2012). Indeed, if hypovita-
minosis D explains in part the patholog-
ical process of AD, it may also enhance
the effectiveness of standard anti-dementia
treatments or account at least partially
for the resistance to these treatments.
Even speculative, this engages clinicians
to replenish vitamin D before starting
anti-dementia treatments or to use vita-
min D as an adjunct to standard treat-
ments. In line with this, a recent 6-month
controlled trial has recently reported that
the combination of memantine + vita-
min D was superior to memantine alone
and vitamin D alone in preventing cog-
nitive decline among AD participants
(Annweiler et al., 2012c). In fact, those tak-
ing bothmolecules had a clinically relevant
and statistically significant gain of 4 points
on the Mini-Mental State Examination.
These results were consistent with an
in vitro experiment, which showed that
cortical axons degenerate less after expo-
sure to amyloid-β peptide or glutamate
in microfluidic neuronal cultures enriched
with memantine plus vitamin D com-
pared to control medium and compared
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FIGURE 1 | Potential neuroprotective roles offered by vitamin D in Alzheimer disease.
to cultures enriched with memantine only
or with vitamin D only (Annweiler et al.,
2014).
CONCLUSIONS
In conclusion, AD is a public health con-
cern due to its very high prevalence and
because the few drugs currently available
are only symptomatic. Current therapeutic
research, which focuses mainly on curative
disease-modifying treatments, addresses a
very small fraction of AD patients, pre-
dominantly those with prodromal disease
and no symptoms of dementia. It is thus
necessary to consider the patients who
already suffer from moderate-to-severe
AD, who constitute the majority of AD
patients. One of the best hopes for them
may rely on the development of multi-
target drugs. In particular, using vitamin
D supplements as an adjunct to stan-
dard anti-dementia treatments appears to
be a simple, inexpensive, and efficient
therapeutic strategy and leads to encour-
aging prospects for the correction of neu-
rological disorders in AD.
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